Published on 5 Nov 2021 on Zacks via Yahoo Finance

Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)

Investors are always looking for stocks that are poised to beat at earnings season and Acceleron Pharma Inc. XLRN, may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Acceleron Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for XLRN in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 87 cents per share for XLRN, compared to a broader Zacks Consensus Estimate of a loss of 96 cents per share. This suggests that analysts have very recently bumped up their estimates for XLRN, giving the stock a Zacks Earnings ESP of +9.14% heading into earnings season.